Profile and investment
| Fund type | Open Ended Investment Company |
|---|---|
| Investment style (stocks) | Market Cap: Large Investment Style: Growth |
| Morningstar category | China Region |
| Launch date | 31 Jan 2018 |
| Price currency | USD |
| Domicile | United States |
| Symbol | KURE |
| Manager & start date | Jonathan Shelon 01 Aug 2018 James Maund 14 Jan 2020 |
| Pricing frequency | Daily |
|---|---|
| Total net assets | 80.29m USD As of Jan 31 2026 |
| Share class size | 80.29m USD As of Jan 31 2026 |
| Net expense ratio | 0.65% |
| Front end load | -- |
| Deferred load | -- |
| Maximum Redemption Fee | -- |
| Min. initial investment | -- |
| Min. additional investment | -- |
| Initial IRA | -- |
| Additional IRA | -- |
| Available for sale | Mexico, United States |
More ▼
Top 5 holdings
| Top 5 holdings as a per cent of portfolio | |||
|---|---|---|---|
| 39.21% | 36.86% | 0.00% | 36.86% |
| Category average | % Net assets | % Short | % Long |
| Company | 1 year change | Portfolio weight | Long allocation |
|---|---|---|---|
| BeOne Medicines AG BEIGF:PKL | -- | 9.38% | |
| Jiangsu Hengrui Pharmaceuticals Co Ltd 600276:SHH | +30.44% | 7.98% | |
| Innovent Biologics Inc IVBXF:PKL | -- | 7.54% | |
| WuXi Biologics (Cayman) Inc WXIBF:PKL | +80.41% | 7.53% | |
| Akeso Inc AKESF:PKL | +50.89% | 4.43% | |
| Per cent of portfolio in top 5 holdings: 36.86% |
Asset type
| Non-US stock | 87.53% |
| US stock | 12.30% |
| Cash | 0.17% |
| US bond | 0.00% |
| Non-US bond | 0.00% |
| Other | 0.00% |
Top 5 sectors
| Healthcare | 98.92% |
| Consumer Defensive | 0.91% |
Top 5 regions
| Emerging Asia | 83.16% |
| United States | 12.30% |
| Developed Asia | 4.37% |
Sector and region weightings are calculated using only long position holdings of the portfolio.
